Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013

  Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013 | Benzinga Benzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn Google+ RSS Free Streaming News Membership is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: Leave blank: already have an account?User LoginI bet you can't wait to get back in here... Username or email: Password: need an account?Forgot password? Contribute Login Sign up Benzinga - Feed Your Mind. HomeBest of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM&ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/FDAMarketsPre-MarketAfter HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong IdeasShort IdeasTechnicalsFrom The PressJim CramerRumorsETFsTechStart-UpsSmall-CapTrading Strategies & Education EarningsGuidanceDividendsM&ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/FDA Market Overview TickersArticlesKeywordsSearch by keyword...googlecse Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013 Charles Gross, Benzinga Staff Writer December 07, 2013 11:16 AM + Follow Print Email Tickers: INFI Share: Infinity Pharmaceuticals (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients withrelapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a potentially fatal hematologic malignancy (blood cancer). Data from the study showedthat IPI-145 was clinically active, with an overall response rate of 73 percent, including three complete responses, among patients receivingIPI-145 dosed at = 25 mg twice daily (BID). Data also showed that 53 percent of patients remained progression free for over one year. Thesedata support DYNAMO, the ongoing Phase 2 study of IPI-145 in patients with refractory iNHL. These findings were presented today at the 55thAnnual Meeting of the American Society of Hematology (ASH).#ASH13See full press releasePosted-In: News Guidance Management Global  Around the Web, We're Loving... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading Techniques for the New Market Enviroment Pope Francis Rips 'Trickle-Down' Economics Come See How the Pro's Trade in this Exclusive Webinar Wynn, MGM, Other Casino Giants Vying For U.S. Turf What Should You Know About AMZN? Most Popular Hottest Tablets For Christmas: iPad Air vs. Nexus 7 vs. Kindle Fire HDX vs. Galaxy Note 10.1 UPDATE: Morgan Stanley Reiterates on InterOil as More Clarity is Needed PlayStation 4, Xbox One Dominance To Be Challenged In 3-4 Years Five Star Stock Watch: Netflix, Inc. 3 Reasons to Buy Suncor Energy InterOil Announces Approval of PRL39 by PNG Government, Clarification on Deal With Total Related Articles (INFI) Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013 Partner Network Get Benzinga's News Delivered Free Zing Talk: Daily Top Stories PreMarket Primer See More » Weekly ETF Outlook Weekly Options Outlook Daily Ratings Summary Posts by Charles Gross Google Developing Nexus TV, According to Sources -The Information Yahoo Acquires EVNTLIVE, Terms Not Disclosed Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013 Most Read Most Recent 1 Hottest Tablets For Christmas: iPad Air vs. Nexus 7 vs. Kindle Fi... 2 UPDATE: Morgan Stanley Reiterates on InterOil as More Clarity is... 3 PlayStation 4, Xbox One Dominance To Be Challenged In 3-4 Years 4 Five Star Stock Watch: Netflix, Inc. 5 3 Reasons to Buy Suncor Energy 6 InterOil Announces Approval of PRL39 by PNG Government, Clarifica... 7 Benzinga's Top #PreMarket Gainers 1 Synthetic Biologics Enters License Agreement with Cedars-Sinai Me... 2 Gilead Reports Positive Data from Interim Phase 2 Results for GS-... 3 SLIDESHOW: iPhone XL, China Mobile Deal And More From The First W... 4 Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013 5 Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Dru... 6 ZIOPHARM Announces Positive Phase 1/2 Interim Results for Ad-RTS-... 7 CommonWealth REIT Files Preliminary Consent Revocation Materials Benzinga Professional Subscribe 10:10 PM China November trade balance data out now $33.80bn surplus (vs. 21.20bn expected) via ForexLive 9:13 PM Google Developing Nexus TV, According to Sources -The Information 9:09 PM Yahoo Acquires EVNTLIVE, Terms Not Disclosed 8:31 PM Bank of Japan (BOJ) Governor Kuroda's 'Mission Accomplished' moment? via ForexLive 8:31 PM World Trade Organization last-minute face-saving compromise "deal" via ForexLive 8:10 PM Hilsenrath: the Fed is 'closer to winding down' QE3 via ForexLive 08:06 PM Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes 08:03 PM Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 1:11 PM China cracking down on foreign currency use in trade financing via ForexLive 11:16 AM Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ASH 2013 11:03 AM Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013 9:56 AM Florida Man Buys $100K Tesla with Bitcoins -CNN Money 09:24 AM ZIOPHARM Announces Positive Phase 1/2 Interim Results for Ad-RTS-IL-12 in Patients With Advanced Melanoma 12:50 AM BOJ's Kuroda speech on Saturday: Offering too complicated forward guidance may be disruptive for markets via ForexLive 12:31 AM 20 lessons in the UK budget statement the tell us everything about how 2014 will play out via ForexLive Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content. Popular ChannelsAnalyst RatingsBe Your Own BossETFsEconomicsForexHotNewsOptionsPress ReleasesStart-upsTechTools & FeaturesAffiliate ProgramBadgesFeedsNews WidgetReal Time FeedSitemapSubmit News TipsAbout BenzingaAbout UsBlogIn the NewsCareersContact UsDisclaimerPrivacy PolicySyndicationTerms and Conditions Benzinga Partners 1 (877) 440-9464 (ZING) Benzinga.com © 2013 SLIDESHOW: iPhone XL, China Mobile Deal And More From The First Week Of December Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013